Patients who DO NOT need Supplemental Oxygen

Warning

Patients who DO NOT need supplemental oxygen for COVID-19 and they have an increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care.

Nirmatrelvir plus Ritonavir (Paxlovid)

NIRMATRELVIR with RITONAVIR is recommended as an option for treating COVID-19 in adults, only if they:

Do not need supplemental oxygen for COVID-19 and

have an increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care.


**Please review interactions and contraindications carefully**

Sotrovimab

SOTROVIMAB is recommended as an option for treating COVID-19 in adults and young people aged 12 years and over and weighing at least 40 kg, only if:

They do not need supplemental oxygen for COVID-19 and

they have an increased risk for progression to severe COVID-19, as defined in the independent advisory group report commissioned by the Department of Health and Social Care and nirmatrelvir plus ritonavir is contraindicated or unsuitable.

Other Therapies

Remdesivir, Molnupiravir – these medications have a conditional recommendation from NICE.

Please review NICE guidelines and consider individual patient characteristics before prescribing.

Editorial Information

Last reviewed: 27/06/2023

Next review date: 26/06/2025

Reviewer name(s): Sarah Connelly.

Document Id: July 2023